Location of Repository

The Role of PPARs in Cancer

By Keisuke Tachibana, Daisuke Yamasaki, Kenji Ishimoto and Takefumi Doi


Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. PPARα is mainly expressed in the liver, where it activates fatty acid catabolism. PPARα activators have been used to treat dyslipidemia, causing a reduction in plasma triglyceride and elevation of high-density lipoprotein cholesterol. PPARδ is expressed ubiquitously and is implicated in fatty acid oxidation and keratinocyte differentiation. PPARδ activators have been proposed for the treatment of metabolic disease. PPARγ2 is expressed exclusively in adipose tissue and plays a pivotal role in adipocyte differentiation. PPARγ is involved in glucose metabolism through the improvement of insulin sensitivity and represents a potential therapeutic target of type 2 diabetes. Thus PPARs are molecular targets for the development of drugs treating metabolic syndrome. However, PPARs also play a role in the regulation of cancer cell growth. Here, we review the function of PPARs in tumor growth

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2435221
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2000). 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory druginduced apoptosis in colorectal cancer cells,”
    2. (1993). A .C .B a y l y ,N .J .F r e n c h ,C .D i v e ,a n dR .A .R o b e r t s ,“ N o n -genotoxic hepatocarcinogenesis in vitro: the FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis,”
    3. (1972). A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues,”
    4. (1998). A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding,”
    5. (1990). A genetic model for colorectal tumorigenesis,”
    6. (2002). A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells,”
    7. (2000). A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions,”
    8. (2004). a n d a r d
    9. (1999). A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis,”
    10. (2006). A novel positive feedback loop between peroxisome proliferator-activated receptor-δ and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth,”
    11. (1999). A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity,”
    12. (2006). A.N arkar ,andR.M.E vans,“PP ARδ:adagger in the heart of the metabolic syndrome,”
    13. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,”
    14. (2004). Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth,”
    15. (2000). Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells,”
    16. (2003). Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome,”
    17. (2004). Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines,”
    18. (2007). Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis,”
    19. (1999). Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells,”
    20. (1998). Activation of t h ep e r o x i s o m ep r o l i f e r a t o r - a c t i v a t e dr e c e p t o rγ promotes the development of colon tumors
    21. (2001). Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells,”
    22. (1998). Activators of the nuclear receptor PPARγ enhance colon polyp formation,”
    23. (2006). Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor γ agonists in cultured cell,”
    24. (1995). An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),”
    25. (1999). andR.A.R obe rts,“ Speciesdifferencesinsequenceandactivity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter,”
    26. (2002). Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway,”
    27. (2001). Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation,”
    28. (2004). Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,”
    29. (1992). APC mutations occur early during colorectal tumorigenesis,”
    30. (2002). APC-dependent suppression of colon carcinogenesis by PPARγ,”
    31. (2002). Apoptosis induced by activation of peroxisomeproliferator activated receptor-gamma is associated with
    32. (2000). Binding of fatty acids and peroxisome proliferators to orthologous fatty acid binding proteins from human, murine, and bovine liver,”
    33. Biosynthesis of enzymes of peroxisomal β-oxidation,”
    34. (2002). Characteristics of the peroxisome proliferator activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells,”
    35. (2002). Characterization of the human PPARα promoter: identification of a functional nuclear receptor response element,”
    36. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2,”
    37. (1999). Cox-2-selective inhibitors: the new super aspirins,”
    38. (2001). Critical roles of PPARβ/δ in keratinocyte response to inflammation,”
    39. (2006). Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression,”
    40. (2003). Cyclooxygenase 2: a molecular target for cancer prevention and treatment,”
    41. (2000). Cyclooxygenases: structural, cellular, and molecular biology,”
    42. (1995). D.J.Mangelsdorf,C.Thummel,M.Beato,etal.,“Thenuclear receptor superfamily: the second decade,”
    43. (1999). Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers,”
    44. (2001). Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α.P P A R α fails to induce peroxisome proliferation-associated genes in human cells independently of the level of receptor expression,”
    45. (1998). Differentiation and reversal ofmalignant changes incolon cancer throughPPARγ,”
    46. (2004). Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor α,”
    47. (1999). Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid,”
    48. (2005). Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma,” Gynecologic Oncology,v o l .9 7 ,n o .2 ,p p .
    49. (2000). Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer,”
    50. (2000). Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer,”
    51. (2002). Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer,”
    52. (1998). Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPARα),”
    53. (2000). Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists,”
    54. (1999). Expression of peroxisome proliferator-activated receptor γ (PPARγ) in human transitional bladder cancer and its role in inducing cell death,”
    55. (2001). Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists,”
    56. (2002). Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists,”
    57. (2008). F.J.GonzalezandY.M.Shah,“PPARα:mechanismofspecies differences and hepatocarcinogenesis of peroxisome proliferators,”
    58. (1997). Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ,”
    59. (2001). Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors α-a n dγ-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus,”
    60. (1997). Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivatordependent receptor ligand assay,”
    61. (1995). Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates,”
    62. (1995). Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor,”
    63. (1999). Fibrates increase human REV-ERBα expression in liver via a novel peroxisome proliferator-activated receptor response element,”
    64. Formation, prevention, and repair of DNA damage by iron/hydrogen peroxide,”
    65. (2002). Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas,”
    66. (1986). G o e l ,N .D .L a l w a n i ,a n dJ .K .R e d d y ,“ P e r o x i s o m e proliferation and lipid peroxidation in rat liver,”
    67. (2005). Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing
    68. (2001). Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells,”
    69. (2001). Griffin ,a n dE .F .J o h n s o n ,“ I d e n t i -fication of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferatoractivated receptor α in HepG2 cells,”
    70. (2002). Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-γ ligands,”
    71. (1976). Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator,”
    72. (2000). Hydrogen peroxide generation in peroxisome proliferator-induced oncogenesis,”
    73. (1980). Hypolipidaemic hepatic peroxisome proliferators form a novel class ofchemicalcarcinogens,”Nature,vol.283,no.5745,pp.397– 398,
    74. (1997). Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,”
    75. (1991). Identification and characterization of the familial adenomatous polyposis coli gene,”
    76. (1998). Identification of cMYC as a target of
    77. (2004). In vivo activation of PPAR target genes by RXR homodimers,”
    78. (2000). Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer,”
    79. (1985). Induction of peroxisomal β-oxidation enzymes in primary cultured rat hepatocytes by clofibric acid,”
    80. (2006). Induction of PPARβ and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPARβ,”
    81. (1905). Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells,”
    82. (2000). Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis,”
    83. (1997). Inhibition of peroxisome proliferator signaling pathways by thyroid hormone receptor. Competitive binding to the responseKeisuke Tachibana et al. 11 element,”
    84. (1984). Inhibitory effect of antioxidants ethoxyquin and 2(3)-tertbutyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator,”
    85. (1991). Interaction of LY171883 and other peroxisome proliferators with fatty-acid-binding protein isolated from rat liver,”
    86. (2002). J.-A.Kim,K.-S.Park,H.-I.Kim,etal.,“Troglitazoneactivates p21Cip/WAF1 through the ERK pathway in HCT15 human colorectal cancer cells,”
    87. (1998). J.A.Brockman,R.A.Gupta,andR.N.DuBois,“Activationof PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells,”
    88. (1992). K l i e w e r ,K .U m e s o n o ,D .J .N o o n a n ,R .A .H e y m a n
    89. (1996). Lessons from hereditary colorectal cancer,”
    90. (2006). Ligand activation of peroxisome proliferator-activated receptor β inhibits colon carcinogenesis,”
    91. (2007). Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth of human N/TERT-1
    92. (1998). Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo,”
    93. (2000). Ligand-dependent interaction of hepatic fatty acid-binding protein with the nucleus,”
    94. (2001). Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both in vitro and in vivo,”
    95. (2001). Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats,”
    96. (1998). Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and
    97. (2000). Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm,”
    98. (2002). Liver fatty acid-binding protein targets fatty acids to the nucleus. Real time confocal and multiphoton fluorescence imaging in living cells,”
    99. (2004). Liver fatty acidbinding protein colocalizes with peroxisome proliferator activated receptor α and enhances ligand distribution to nuclei of living cells,”
    100. (1991). locus genes from chromosome 5q21,”
    101. (1999). Loss-of-function mutations in PPARγ associated with human colon cancer,”
    102. (1993). M i y a t a ,B .Z h a n g ,S .L .M a r c u s ,J .P .C a p o n e ,a n dR
    103. (1996). M.Oshima,J.E.Dinchuk,S.L.Kargman,etal.,“Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2
    104. (2004). Mechanisms of gene silencing by double-stranded
    105. (1994). Mechanisticallybased human hazard assessment of peroxisome proliferatorinduced hepatocarcinogenesis,”
    106. (2007). microRN A sa so n c o g e n e sa n dt u m o rs u p p r e s s o r s ,
    107. (1995). Mode of action of peroxisome proliferators as hypolipidemic drugs.
    108. (1994). mPPARγ2: tissue-specific regulator of an adipocyte enhancer,”
    109. (1998). Multiple parameters determine the specificity of transcriptional response by nuclearreceptorsHNF-4,ARP-1,PPAR,RARandRXRthrough common response elements,”
    110. (1965). Nature of the hepatomegalic effect produced by ethyl-chlorophenoxy-isobutyrate in the rat,”
    111. Novel expression and function of peroxisome proliferatoractivatedreceptorgamma(PPARγ)inhumanneuroblastoma cells,”ClinicalCancerResearch,vol.7,no.1,pp.98–104,2001.
    112. (2002). Nuclear receptor corepressor-dependent repression of peroxisomeproliferator-activated receptor δ-mediated transactivation,”
    113. (2006). o r i m u r a ,C .C h e u n g ,J .M .W a r d ,J .K .R e d d y ,a n dF .J . Gonzalez, “Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis,”
    114. (2002). o s s n e r ,U .S c h u l z ,U .K r¨ uger, et al., “Agonists of peroxisome proliferator-activated receptor γ inhibit cell growth
    115. (2001). Onaya,“Ligandsforperoxisomeproliferator-activatedreceptorγ inhibitgrowthandinduceapoptosisofhumanpapillary thyroid carcinoma cells,”
    116. (2007). Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors,”
    117. (2002). Oxidative nucleotide damage: consequences and prevention,”
    118. (1998). P e t e r s ,T .A o y a m a ,R .C .C a t t l e y ,U .N o b u m i t s u
    119. (1994). Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2,”
    120. (1998). Peroxisome proliferator activated receptor-α expression in human liver,”
    121. (2004). Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes,”
    122. (2007). Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation,”
    123. (2001). Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis,”
    124. (2001). Peroxisome proliferator-activated receptor γ ligand-induced growth inhibition of human hepatocellular carcinoma,”
    125. (2003). Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice,”
    126. (2002). Peroxisome proliferator-activated receptor γ reduces the growth rate of pancreatic cancer cells through the reduction of cyclin
    127. (2006). Peroxisome proliferator-activated receptor δ (PPARδ), a novel target site for drug discovery in metabolic syndrome,”
    128. (2005). Peroxisome proliferator-activated receptor δ and γ agonists differentially alterKeisuke Tachibana et al. 13 tumor differentiation and progression during mammary carcinogenesis,”
    129. (2007). Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines,”
    130. (2008). Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of
    131. (2005). Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation,”
    132. (2004). Peroxisome proliferator-activated receptor-γ ligands as cellcycle modulators,”
    133. (2004). Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis,”
    134. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells,”
    135. (1999). Peroxisome proliferator-activated receptors: nuclear control of metabolism,”
    136. (2001). Peroxisome proliferator-activated receptorα activation and high-density
    137. (2005). Peroxisome proliterator-activated receptors in squamous cell carcinoma and its precursors,”
    138. (2003). Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,”
    139. (1996). PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,”
    140. (2006). PPARβ/δ selectively induces differentiation and inhibits cell proliferation,”
    141. (2001). PPARγ agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells,”
    142. (2004). PPARγ signaling exacerbates mammary gland tumor development,”
    143. (1998). PPARγ3m R N A :a distinctPPARγ mRNAsubtypetranscribedfromanindependent promoter,”
    144. (2003). PPARδ is a very low-density lipoprotein sensor in macrophages,”
    145. (1999). PPARδ is an APC-regulated target of nonsteroidal antiinflammatory drugs,”
    146. (2004). PPARδ status and Apc-mediated tumourigenesis in the mouse intestine,”
    147. (2007). Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer,”
    148. (2001). Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs),”
    149. (2001). Prostacyclin-dependent apoptosis mediated by PPARδ,”
    150. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer,”
    151. (2004). Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ,”
    152. (2001). ProstaglandinE2 increases growthandmotilityofcolorectal carcinoma cells,”
    153. (2006). RB and cell cycle progression,”
    154. (2003). Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor β/δ,”
    155. (2005). Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrateinduced hepatocarcinogenesis and cholestasis,”
    156. (1997). Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator
    157. (1996). Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression,”
    158. (2002). Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription,”
    159. (2000). Soames, andR.A.R oberts,“ Speciesdifferencesinresponsetodiethylhexylphthalate: suppression of apoptosis, induction of DNA synthesis and peroxisome proliferator activated receptor alpha-mediated gene expression,”
    160. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcriptionfactor,”Cell,vol.79,no.7,pp.1147–1156,1994.
    161. (1994). Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin,”
    162. (1992). T u g w o o d ,I .I s s e m a n n ,R .G .A n d e r s o n ,K .R .B u n d e l l
    163. (2006). Targeted induction of apoptosis for cancer therapy: current progress and prospects,”
    164. (2005). Targeting the cell cycle: a new approach to cancer therapy,”
    165. (2004). Targeting the mitogenactivated protein kinase cascade to treat cancer,”
    166. (1998). Terminal differentiation of human breast cancer through PPARγ,”
    167. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisomeproliferator-activatedreceptorγ andtheretinoid Xr ec ept o r , ”ProceedingsoftheNationalAcademyofSciencesof theUnitedStatesofAmerica,vol.94,no.1,pp.237–241,1997.
    168. (2003). The 15-lipoxygenase1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells,”
    169. (2005). The human peroxisome proliferator-activated receptor δ gene is a primary target of 1α,25-dihydroxyvitamin D3 and its nuclear receptor,”
    170. (2005). The many faces of PPARγ,”
    171. (2007). The many ways of Wnt
    172. (1998). The nuclear receptors peroxisome proliferator-activated receptor α and rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates,”
    173. (1997). The organization, promoter analysis, and expression of the human PPARγ gene,”
    174. (1999). The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs,” Carcinogenesis,
    175. (2002). The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling,”
    176. (2008). The PPARα-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPARα,”Toxicological Sciences,
    177. (2007). The role of fibrates in the prevention of cardiovascular disease—a pooled meta-analysis of long-term randomized placebo-controlled clinical trials,”
    178. (2006). The toxicology of ligands for peroxisome proliferator-activated receptors
    179. (2005). Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R,”
    180. (1986). Transcriptional regulation of peroxisomal fatty acyl-CoA oxidase and enoylCoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators,”
    181. (2003). Transcriptional repression of atherogenic inflammation: modulation by PPARδ,”
    182. (2005). Transcriptional repression of peroxisome proliferator-activated receptor β/δ in murine keratinocytes by CCAAT/enhancerbinding proteins,”
    183. Transformation of mammalian cells by overexpressing H2O2-generating peroxisomal fatty acyl-CoA oxidase,”
    184. (2000). Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists,”
    185. (2001). Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators,”
    186. (1991). Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene,”
    187. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas,”
    188. (1984). Use of primaryculturesofadultrathepatocytestoinvestigatemechanisms of action of nafenopin, a hepatocarcinogenic peroxisome proliferator,”
    189. (2007). Utilization of DR1 as true RARE in regulating the Ssm, a novel retinoic acid-target gene in the mouse testis,”
    190. (2000). W i l l s o n ,P .J .B r o w n ,D .D .S t e r n b a c h ,a n dB .R .H e n k e , “The PPARs: from orphan receptors to drug discovery,”
    191. (1999). β-catenin regulates expression of cyclin D1 in colon carcinoma cells,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.